Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHANTOM study of STN1010904 ophthalmic suspension in Fuchs endothelial corneal dystrophy
2024-517104-11-00Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of STN1010904 in Fuchs endothelial dystrophy (FED) (3 arms), sponsored by Santen Pharmaceutical. Primary endpoints: Change from baseline in best-corrected visual acuity at 100% contrast at Month 18, Change from baseline in best-corrected visual acuity at 10% contrast at Month 18 and 2 more. Started Oct 2024; status: completed.
02
Drugs
STN1010904
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on 2024-517104-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517104-11-00.